This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

10 Companies That Prove Stock Picking Is Still Alive

10. Teradata (TDC)

Company profile: Teradata, with a market value of $13 billion, is a 32-year-old IT company focused on developing and commercializing data warehousing services to the world's largest 3,000 organizations. It was spun off from NCR Corp. in 2007.

Investor takeaway: Its shares are up 57% this year and have a three-year, average annual return of 43%. Analysts give its shares six "buy" ratings, seven "buy/holds," and seven "holds," according to a survey of analysts by S&P.

S&P has it rated "hold," based on valuation, but adds that "we continue to see many positives for the company." Analysts' consensus estimate is for earnings of $2.80 per share this year, growing by 14% to $3.19 per share next year.

9. Discover Financial Services (DFS)

Company profile: Discover Financial, with a market value of $19 billion, issues credit cards and acquires transactions. It operates a closed-loop credit card network and also uses third parties to issue its cards. The company's sales growth has averaged about 2% a year over the past 14 years.

Dividend Yield: 1%

Investor takeaway: Its shares are up 58% this year and have a three-year, average annual return of 47%. Analysts give its shares 10 "buy" ratings, six "buy/holds," and eight "holds," according to a survey of analysts by S&P.

In March, the company announced a strategy shift toward becoming a more full-service direct-payments provider. Morningstar says the trend of moving from cash and checks to electronic payments, such as credit or debit cards, "is a major tailwind for Discover."

8. Sherwin-Williams Co. (SHW)

Company profile: Sherwin-Williams, with a market value of $14 billion, makes paints, coatings and wall coverings worldwide. It is the U.S. market leader, with a 30% share.

Dividend Yield: 1.09%

Investor takeaway: Its shares are up 59% this year and have a three-year, average annual return of 34%. Analysts give its shares one "buy" ratings, one "buy/hold," 11 "holds," and one "weak hold," according to a survey of analysts by S&P.

S&P has it rated "sell" given its high valuation as it has a $112 price target on it, but its shares are at $140. 67. Earnings are strong as analysts' consensus is for $6.36 per share this year, and that they will grow by 19%, to $7.59, next year.

7. Apple (AAPL)

Company profile: Apple, with a market value of $621 billion, designs and makes consumer electronic devices, including PCs (Mac), tablets (iPad), phones (iPhone) and portable music players (iPod). Its iTunes online store is the largest music distributor in the world; it sells and rents TV shows and movies, and sells applications for the iPhone and iPad.

Dividend Yield: 0.4%

Investor takeaway: Its shares are up 61% this year and have a three-year, average annual return of 60%. Analysts give its shares 34 "buy" ratings, 15 "buy/holds," three "holds," and two "sells," according to a survey of analysts by S&P.

S&P has it rated "buy" with an $800 price target, a 23% premium to the current price. S&P says its projected earnings growth, large cash position, strong free cash flow generation and relatively high return on equity, continues to make the shares "attractive."

Morningstar analyst Michael Holt writes that, although the company's recent third-quarter results were below expectations "because of an unexpectedly sharp drop in iPhone shipments, we believe the headwinds are primarily short-term in nature and product-cycle driven." He also said that long-term, that "as users become more tethered to Apple's iOS ecosystem rather than a specific device, integrating additional Apple devices into users' routines becomes seamless."

6. Vertex Pharmaceuticals (VRTX)

Company profile: Vertex Pharmaceuticals, with a market value of $12 billion, is a biopharmaceutical company that uses structure-based drug design to discover and develop small molecule therapeutics for the treatment of a wide range of diseases, including hepatitis C and cystic fibrosis.

Investor takeaway: Its shares are up 65% this year and have a three-year, average annual return of 17.5%. Analysts give its shares 10 "buy" ratings, nine "buy/holds," and six "holds," according to a survey of analysts by S&P.

S&P has it rated "buy" with a $62 price target, a 13% premium to its current price. Analysts' consensus estimate is for earnings of $1.82 per share this year, growing by 2% to $1.86 per share next year.

2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,982.59 +22.02 0.13%
S&P 500 1,978.91 +0.57 0.03%
NASDAQ 4,444.9090 -4.6550 -0.10%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs